RE: RNS5 May 2022 14:06
LONDON, UK / ACCESSWIRE / May 5, 2022 / Apollon Formularies plc (AQSE:APOL) (“Apollon” or the “Company”), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE:AION) (“Aion”), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that Apollon has acquired certain intellectual property from AI Pharmaceuticals Ltd., a wholly owned Jamaican subsidiary of Aion.
Under the terms of the Agreement, Apollon will acquire the following patents and all associated supporting data including the pre-clinical testing results from BIOENSIS.
Compositions and Methods for Treatment of Cancers.
Compositions and Methods for Treatment of Inflammation.
Methods for Treatment of Human Cancers using Mushroom Compositions.
Methods for Treatment of Human Cancers using Cannabis Compositions.
Apollon has purchased the patents from Aion via a cash payment of £95,957.18 and the issuing of 4,348,679 ordinary shares in the Company. These ordinary shares will be subject to a complete trading restriction for a period of six (6) calendar months from the date of the stock transfer. After the six (6) month restriction period, twenty percent (20%) of such stock received will become eligible for trading, and an additional twenty percent (20%) will be tradable at the end of each following three-month period, with all trading restrictions being fully removed at the end of eighteen (18) months.
Read more: https://www.digitaljournal.com/pr/apollon-acquires-intellectual-property-from-aion#ixzz7SPkaxhbY
Sign In
Follow the stocks
